Senior Editors

Dr. Sung-Ju Moon

Chief Strategy Officer, IntoCell

Dr. Sung-Ju Moon is a medicinal chemistry expert with 25 years of R&D experience, including 20 years in the biopharmaceutical industry specializing in ADCs. He earned his Ph.D. from Seoul National University and conducted postdoctoral research at UT Austin and University of Virginia.

As a Senior Scientist at Immunomedics, he helped develop Trodelvy™ for metastatic breast cancer, earning the 2014 Thomas Edison Patent Award. At Astellas Pharma, he contributed to 10+ ADC projects, including Padcev™, and secured multiple patents. At Ambrx Biopharma, he advanced immune-stimulating antibody conjugates, bispecific Fab, and ADC drug libraries.

Now CSO at IntoCell, he leads next-gen ADC development and strategic partnerships, securing licensing deals with ADCT, Samsung Bioepis, and ABL.

Vincent Rotello

Professor of Chemistry, University of Massachusetts Amherst

Vincent Rotello is the Charles A. Goessmann Professor of Chemistry and a University Distinguished Professor at UMass Amherst. He earned his B.S. from Illinois Institute of Technology (1985) and Ph.D. from Yale (1990), followed by an NSF postdoctoral fellowship at MIT. Since joining UMass in 1993, he has received numerous awards, including the Arthur C. Cope Scholar Award (2023) and the Transformational Research and Excellence in Education Award (2016). A Fellow of AAAS and the Royal Society of Chemistry, he is a Highly Cited Researcher (2014–2024). His research bridges synthetic organic chemistry and biology, focusing on nanotechnology, bioconjugation, nanomedicine, and diagnostics, with over 690 peer-reviewed papers published.

Editorial Advisory Board

Kalli Catcott

Principal Scientist, Mersana Therapeutics

Kalli has been bringing biomolecules together since 2007. She is currently a Principal Scientist Mersana Therapeutics where she works on developing new ADCs in the Research Bioconjugation Department. She has also worked at ImmunoGen, Amgen, and Life Technologies investigating all types of protein conjugates. Kalli holds a PhD in Chemistry from Northeastern University and a BS in Biochemistry from UC San Diego.

Ning Wang

Bioinformatics Scientist, Arcus Biosciences

Ning is a seasoned computational biologist and bioinformatics scientist. His expertise lies in leading translational and clinical oncology studies, with a specialty in preclinical studies including drug target identification and tumor model selection. He has contributed significantly to bioinformatics analyses in various oncology clinical trials, focusing on biomarker discovery and patient stratification. His leadership extends to the realm of genomic data, where he has spearheaded real-world data efforts and coordinated the work of postdoctoral-level personnel. Ning holds a PhD in Bioinformatics from UCLA.

Rakesh Dixit

Cofounder, President, and CSO, Regio Biosciences

Rakesh is Cofounder, President, and CSO of Regio Biosciences, a spin-off of AstraZeneca, focused on developing therapies to reduce plaque burden and reverse cardiovascular disease. He is also President & CEO of BIONAVIGEN, a virtual drug development company. Previously, he was VP of Biologics Safety Assessment at AstraZeneca and held leadership roles at Merck, Johnson & Johnson, and MedImmune. Dixit played a pivotal role in developing 10 marketed biopharmaceuticals and contributed to over 100 INDs and 15 BLA/NDA approvals. A recognized expert in bioconjugates, he has led the development of multiple ADC therapies, successfully filing INDs for over 10 ADC drugs. He has published 80+ papers, delivered 130+ global presentations, and received PharmaVoice’s 100 Most Inspiring People award and the prestigious Long-Standing Contribution to ADCs award.

Roy D. Baynes, MD, PhD

Chief Medical Officer, Merck Research Laboratories

Roy Baynes is Senior Vice President Global Clinical Development and Chief Medical Officer at Merck Research Laboratories in Rahway, New Jersey. He was previously Senior Vice President of Oncology, Inflammation and Respiratory Therapeutics at Gilead Sciences and prior to that was Vice President Global Clinical Development and Therapeutic Area (TA) Head for Hematology / Oncology, at Amgen Inc. In the early years of his tenure at Amgen before becoming TA head of Hematology / Oncology in Clinical Development he was TA head for Hematology / Oncology in Global Medical Affairs.He graduated as a Medical Doctor and obtained a Master of Medicine and Doctor of Philosophy from the University of the Witwatersrand, Johannesburg, South Africa. He has had a long and distinguished career in the haematology-oncology-and stem cell transplantation fields, including drug development, basic research, clinical practice, clinical research, teaching and administration. He is a member of many international societies, including the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO), and has authored some 150 publications. He has been recurrently named among America’s top physicians. Before joining Amgen in 2002, he was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute, an NCI designated Comprehensive Cancer Center, at Wayne State University, Detroit, Michigan, USA.

Esohe Idusogie

VP of Global Quality Control and Analytical Chemistry, ADC Therapeutics

Esohe has over 25 years of hands-on and management experience in the biopharmaceutical industry, supporting the development of biological products, including monoclonal antibodies and antibody-drug conjugates. She has led analytical teams and managed CMC projects from the preclinical stage through commercialization.

She has extensive experience in method development and validation, including bioanalytical and bioassay development, validation, and technology transfer. Esohe has established new analytical, bioassay, and bioanalytical laboratories and systems to support process development and assay transfer to GLP and GMP laboratories.

Additionally, she has selected, managed, and audited GMP and GLP contract testing laboratories in support of manufacturing, method validation, method transfer, QC release, and stability testing. Throughout her career, Esohe has authored and reviewed regulatory documents for multiple IND filings and late-phase programs, including BLA filings.

Elizabeth Love

Scientific Leader of ADC Platforms, GSK

Elizabeth has 15 years' experience in the field of ADCs and bioconjugation in both industry and academia. Currently she is a Scientific Leader in the antibody-drug conjugate platform team within Large Molecule Discovery at GSK. In this role, she leads on the analytical characterization strategy of ADCs in discovery, in addition to leading pipeline ADC programs and innovation strategies. Previously Elizabeth was a Team Leader at LifeArc, and holds a PhD from UCL, where she worked in the research groups of Prof Jamie Baker and Prof Kerry Chester.